| MSCI |
Report |
Adjusted EPS |
BEAT |
pred ~$4.98 vs. cons $4.89 |
MEDIUM |
| MSCI |
Report |
Total Revenue |
BEAT |
pred ~$888M vs. cons $877M |
MEDIUM |
| MSCI |
Report |
Asset-Based Fee (ABF) run-rate |
BEAT |
pred ~$905M vs. cons ~$895M |
MEDIUM |
| MSCI |
Guide |
FY2026 Adjusted EBITDA expense guidance |
UNCHANGED |
guide ~$1,325M (top-half of $1,305-1,335M range) vs. cons $1,320M (FY2026) |
MEDIUM |
| MSCI |
Guide |
FY2026 Free Cash Flow guidance |
BETTER |
guide ~$1,510M vs. cons $1,495M (FY2026) |
LOW |
| MSCI |
Guide |
Q3 2026 Effective tax rate guidance |
UNCHANGED |
guide ~19% vs. cons ~19% (Q3 2026) |
MEDIUM |
| MSCI |
Guide |
Q3 2026 Analytics revenue growth commentary |
UNCHANGED |
guide ~6% vs. cons ~6% (Q3 2026, run-rate high-single-digit better read-through) |
LOW |
| MSCI |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
MEDIUM |
| MSCI |
Return |
5-day cumulative residual |
-0.9% (FADE) |
A likely beat on EPS/revenue/ABF run-rate is already substantially priced in after the stock's run to 52-week highs and a wave of sell-side price-target hikes (Raymond James $760, Barclays $735) ahead of the print. With guidance items (opex, tax rate, FCF) largely reiterated rather than raised and the guided Analytics deceleration already flagged, there's limited fresh upside catalyst for out-quarter estimate revisions. At ~34x trailing earnings, any softness in period-end AUM snapshot (given the late-June equity dip) or lack of explicit raise to full-year guidance should trigger profit-taking/mean-reversion over the following days, consistent with a 'sell-the-news' fade after an initial modest positive pop. |
MEDIUM |